Earnings Releases·Nov 4, 2026, 7:04 AM ET

Charles River Laboratories — Third Quarter 2026 Earnings Summary

Reported Q3 revenue of $982.7 million (down 2.2% YoY), with organic growth of 4.7% YoY; GAAP EPS rose to $6.86 (vs. $1.10) and Non-GAAP EPS increased 27.2% to $3.09, driven by a $245.6 million tax reserve reversal and improved margins.
Raised full-year 2026 guidance across all metrics: revenue decline narrowed to 2.0–1.5% (from 3.5–2.5%), organic growth raised to at least +1.5%, GAAP EPS to $8.15–$8.35, and Non-GAAP EPS to $11.35–$11.55.
Completed divestitures of CDMO, Cell Solutions, and European Discovery sites; utilized $324.1 million for treasury stock purchases and recognized a $38.5 million gain on asset sales.
Strategic initiatives include the "Pathway to Purpose" vision, new product launches (Endosafe Automated Suite, Apollo Orchestrate™), and an FDA collaboration to validate preclinical screening tools.